AMWatch

Danmarks største venturefond: Sådan investerer vi i life science

Novo Seeds kaster hvert år hundredevis af millioner efter lovende unge startups og iværksættere inden for life science. Men hvad skal der til for at komme i fondens søgelys, hvordan foregår samarbejdet, og hvad er kriterierne for succes? Partner i fonden, Stephan Christgau, løfter her en del af sløret.

Stephan Christgau (foto) er partner i Novo Seeds, som hvert år investerer for hundredevis af mio. i danske life science startups. | Photo: Privat, PR

Det en var en glædens dag for Novo Seeds, da Orphazyme som det første danske biotekselskab siden 2010 gik på børsen i Danmark sidste år.

Orphazyme blev startet med først et pre-seed, dvs. en bevilling fra Novo Nordisk Fonden og dernæst en seed investering fra Novo Seeds med ejerskab på almindelige venture betingelser. Uden støtten og investeringen havde holdet bag Orphazyme formodentlig ikke kunne ringe med børs-klokken den dag tilbage i 2017.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Oil services investments and inflows help BankInvest in Q1

Net inflows have exceeded expectations at BankInvest in Q1. The EUR 20bn manager has been criticized for some of the investments in its sustainable flagship product, but CEO Lars Bo Bertram is proud that the EUR 12bn fund has managed to beat its benchmark despite massive gains for oil and gas.

Latest news

AMWatch job

See all jobs

See all jobs

Watch job

See all jobs

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch